KemPharm Inc (NASDAQ:KMPH) – Analysts at Oppenheimer issued their Q1 2018 EPS estimates for KemPharm in a note issued to investors on Sunday. Oppenheimer analyst D. Archila anticipates that the specialty pharmaceutical company will earn ($0.65) per share for the quarter. Oppenheimer currently has a “Buy” rating and a $13.00 price target on the stock. Oppenheimer also issued estimates for KemPharm’s Q2 2018 earnings at ($0.65) EPS, Q3 2018 earnings at ($0.39) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($1.81) EPS, FY2019 earnings at ($1.66) EPS, FY2020 earnings at ($2.03) EPS and FY2021 earnings at ($1.42) EPS.
KMPH has been the subject of several other reports. ValuEngine upgraded KemPharm from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Zacks Investment Research cut KemPharm from a “buy” rating to a “hold” rating in a research note on Thursday, November 16th. Canaccord Genuity set a $11.00 target price on KemPharm and gave the stock a “buy” rating in a research note on Friday, February 23rd. Finally, Royal Bank of Canada set a $9.00 target price on KemPharm and gave the stock a “buy” rating in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and a consensus target price of $9.15.
Several institutional investors and hedge funds have recently made changes to their positions in KMPH. C WorldWide Group Holding A S lifted its stake in shares of KemPharm by 14.1% in the 3rd quarter. C WorldWide Group Holding A S now owns 435,528 shares of the specialty pharmaceutical company’s stock valued at $1,611,000 after acquiring an additional 53,829 shares during the last quarter. Victory Capital Management Inc. lifted its stake in shares of KemPharm by 26.7% in the 4th quarter. Victory Capital Management Inc. now owns 162,077 shares of the specialty pharmaceutical company’s stock valued at $656,000 after acquiring an additional 34,114 shares during the last quarter. Finally, Alyeska Investment Group L.P. lifted its stake in shares of KemPharm by 1.8% in the 3rd quarter. Alyeska Investment Group L.P. now owns 992,338 shares of the specialty pharmaceutical company’s stock valued at $3,672,000 after acquiring an additional 17,721 shares during the last quarter. Institutional investors own 36.33% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this piece on another website, it was illegally copied and reposted in violation of US & international copyright laws. The legal version of this piece can be read at https://www.tickerreport.com/banking-finance/3227726/q1-2018-earnings-forecast-for-kempharm-inc-kmph-issued-by-oppenheimer.html.
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.